'Rituximab' presentation slideshows

RTP TV: An 8-Part Live CME Webcast Series

913 views • 78 slides

New Evidence reports on presentations given at ASH 2010

New Evidence reports on presentations given at ASH 2010. Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion, Long-term Follow-up of R-chemo in DLBCL, and New Modalities.

855 views • 71 slides

Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and

New Evidence reports on presentations given at ACR/ARHP 2010. Efficacy and Safety of Rituximab in the Treatment of Rheumatoid Arthritis and ANCA-associated Vasculitis. Report on ACR/ARHP 2010 presentations.

900 views • 68 slides

902 views • 46 slides

Expanded Horizons: Long-Term Treatment with Selective B Cell Therapy

Expanded Horizons: Long-Term Treatment with Selective B Cell Therapy. Paul Emery arc Professor of Rheumatology, Academic Unit of Musculoskeletal Disease, University of Leeds, Leeds Teaching Hospitals Trust, Leeds, UK. Rituximab. Efficacy demonstrated in Phase II/III trials

581 views • 43 slides

Monoclonal Antibodies in Cancer Treatment

Monoclonal Antibodies in Cancer Treatment. Monoclonal Antibody Therapy for Cancer. FDA approved:. Rituximab anti-CD20 lymphoma Herceptin anti-her2/neu breast cancer Myelotarg anti-CD33 AML Campath anti-CD52 CLL Zevalin 90 Y anti-CD20 lymphoma Bexxar 131 I anti-CD20 lymphoma.

2.14k views • 41 slides

Update: New Treatment Modalities

A S H. 2 0 0 8. Update: New Treatment Modalities. ASH 2008 : Update on new treatment modalities. GA101 Improves tumour growth inhibition in mice and exhibits a promising safety profile in patients with CD20+ malignant disease

577 views • 40 slides

Rituximab in the Treatment of Other Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML 2011. Rituximab in the Treatment of Other Lymphoproliferative Disorders. Report on EHA/ICML 2011 presentations.

530 views • 39 slides

Chairman of the Dutch Hematology Society Chairman of the HOVON CLL Group

Marinus van Oers Professor of Hematology/Head of the Department of Clinical Hematology, Academic Medical Center, University of Amsterdam, The Netherlands. Chairman of the Dutch Hematology Society Chairman of the HOVON CLL Group

569 views • 38 slides

Klinikum Grosshadern

609 views • 35 slides

Faculty

Consensus or Controversy? Investigator Perspectives on Practical Issues and Research Questions in Non-Hodgkin Lymphoma Friday, December 6, 2013 1:00 PM - 3:30 PM New Orleans, Louisiana. Moderator. Neil Love, MD. Faculty. Brad S Kahl, MD Mitchell R Smith, MD, PhD Steven M Horwitz, MD.

503 views • 34 slides

Rituximab efficacy in other haematological malignancies

Rituximab efficacy in other haematological malignancies. Christian Buske. CLL. Dose escalation of rituximab for CLL: response in patients with CLL. Response rate (%). (n=39)*. (n=24)*. (n=7)*. (n=9)*. Rituximab (mg /m 2 ). * Evaluable patients.

473 views • 32 slides

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma

Follicular Lymphoma Transformed Lymphoma Diffuse Large B-Cell Lymphoma. John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Professor of Medicine, Weill Cornell Medical College Associate Director, Weill Cornell Cancer Center.

829 views • 30 slides

350 views • 27 slides

1 Martin P et al. Proc ICML 2013;Abstract 063. 2 Morschhauser F et al.

410 views • 18 slides

An innovative approach to RA : Efficacy and safety of B cell therapy

An innovative approach to RA : Efficacy and safety of B cell therapy. Professor Patrick DUREZ Royal Belgian Society of Rheumatology Aalst 2007. TNF failure: what options do we have?. Persistent synovitis. B cell. B cell. B cell. Plasma cell. IL-10. IL-6. Dendritic cell. TNF- a.

318 views • 16 slides

Kahl BS et al. Proc ASH 2012; Abstract 153.

251 views • 11 slides

Salles GA et al. Proc ASCO 2010;Abstract 8004.

Rituximab Maintenance for 2 Years in Patients with Untreated High Tumor Burden Follicular Lymphoma After Response to Immunochemotherapy. Salles GA et al. Proc ASCO 2010;Abstract 8004. Introduction.

258 views • 11 slides

Westin JR et al. Proc ASH 2012; Abstract 793.

Phase II Safety and Efficacy Study of CT-011, a Humanized Anti-PD-1 Monoclonal Antibody, in Combination with Rituximab in Patients with Relapsed Follicular Lymphoma. Westin JR et al. Proc ASH 2012; Abstract 793. Background.

284 views • 9 slides

Ardeshna KM et al. Proc ASH 2010 ; Abstract 6.

An Intergroup Randomised Trial of Rituximab versus a Watch & Wait Approach in Patients with Advanced Stage, Asymptomatic, Non-bulky Follicular Lymphoma. Ardeshna KM et al. Proc ASH 2010 ; Abstract 6. Eligibility. Follicular lymphoma Grade 1, 2, 3a Stage II, III, IV

213 views • 8 slides